Mira Pharmaceuticals (MIRA) Net Income towards Common Stockholders (2024 - 2025)
Mira Pharmaceuticals (MIRA) posted Net Income towards Common Stockholders of -$6.0 million for Q4 2025, up 73.64% sequentially from -$22.7 million in Q3 2025, and down 149.34% YoY from $12.1 million in Q4 2024.
Mira Pharmaceuticals (MIRA) Net Income towards Common Stockholders (2024 - 2025) Analysis & Trends
Mira Pharmaceuticals (MIRA) has 2 years of Net Income towards Common Stockholders data on file, last reported at -$6.0 million in Q4 2025.
- Quarterly Net Income towards Common Stockholders fell 149.34% year-over-year to -$6.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$28.7 million (down 545.38% YoY) and the FY2025 annual result came in at -$32.0 million, down 307.5% from the prior year.
- Net Income towards Common Stockholders rose to -$6.0 million in Q4 2025 per MIRA's latest filing, from -$22.7 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was -$2.0 million in Q3 2024, with the low at -$22.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 7.40 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 5.24 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 697.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 47.33 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -4.21 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -13.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 1.65 |
| 10 | Mira Pharmaceuticals | 22.51 Mn | 11.48 Mn | - | -5.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.98 Mn |
| Sep 30, 2025 | -22.69 Mn |
| Dec 31, 2024 | -2.40 Mn |
| Sep 30, 2024 | -2.04 Mn |